Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854726 | 1.00 | FGFR1 (0.35) | FGFR1FGFR4DGAT1MAPTENPP3 | |
| SCHEMBL13521539 | 0.84 | DGAT1 (0.35) | DGAT1MAPTNPC1DUTEGFR | |
| SCHEMBL29940970 | 0.84 | DGAT1 (0.37) | DGAT1MAPTNPC1DUTEGFR | |
| SCHEMBL31710459 | 0.84 | DGAT1 (0.35) | DGAT1MAPTNPC1DUTEGFR | |
| SCHEMBL2884544 | 0.84 | DGAT1 (0.35) | DGAT1MAPTNPC1DUTEGFR | |
| SCHEMBL101528 | 0.84 | DGAT1 (0.40) | DGAT1MAPTNPC1DUTEGFR | |
| SCHEMBL29514152 | 0.84 | DGAT1 (0.40) | DGAT1MAPTNPC1DUTEGFR | |
| SCHEMBL18559451 | 0.83 | FGFR1 (0.35) | FGFR1FGFR4ENPP3ENPP1 | |
| SCHEMBL21632543 | 0.82 | MAPT (0.35) | DGAT1MAPTNPC1EGFRIGF1R | |
| SCHEMBL21632481 | 0.82 | DGAT1 (0.36) | DGAT1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747250-A1 | KINASE INHIBITORS | The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12583856-B2 | Inhibitors of protein kinase A | BLUEPRINT MEDICINES CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| US-12473284-B2 | Small molecule inhibitors of ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250177382-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-12240844-B2 | Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease | VORONOI, INC. (KR) | 2025-03-04 | — | — | US | disclosed |
| WO-2025019585-A1 | KINASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20250011299-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-01-09 | — | — | US | disclosed |
| US-20240400551-A1 | NEK7 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| CN-118201915-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1742945-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | Bayer HealthCare AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060183906-A1 | Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile | INCYTE CORPORATION | 2006-08-17 | — | — | US | disclosed |
| WO-2006069080-A2 | PYRROLO[2,3-B]PYRIDIN-4-YL-AMINES AND PYRROLO[2M3-B]PYRIMIDIN-4-YL-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006004636-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240844-B2 | Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease | CLK1, CLK2, CLK3 | FGFR1 979/4885FGFR4 1789/4885DGAT1 4258/4885 |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | FGFR1 438/4885FGFR4 737/4885DGAT1 3798/4885 |
| US-20060183906-A1 | Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile | JAK1, ZAP70, LCK | FGFR1 2985/4885FGFR4 1768/4885DGAT1 1996/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | FGFR1 650/4885FGFR4 1525/4885DGAT1 3356/4885 |
| US-12473284-B2 | Small molecule inhibitors of ULK1 | ULK1, ULK2, ULK3 | FGFR1 1645/4885FGFR4 1991/4885DGAT1 2993/4885 |
| US-20250177382-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | FGFR1 4396/4885FGFR4 4618/4885DGAT1 4536/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | FGFR1 438/4885FGFR4 737/4885DGAT1 3798/4885 |
| US-12583856-B2 | Inhibitors of protein kinase A | CSNK1A1, CSNK1A1L, CSNK1G1 | FGFR1 510/4885FGFR4 1424/4885DGAT1 3074/4885 |
| US-20250011299-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | FGFR1 35/4885FGFR4 109/4885DGAT1 3593/4885 |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, ALK | FGFR1 43/4885FGFR4 122/4885DGAT1 4181/4885 |
| US-20240400551-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | FGFR1 4312/4885FGFR4 4523/4885DGAT1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.